IL10 and colitis: However, butyrate supplementation did not protect Il22−/− mice from DSS-induced colitis, although butyrate treatment in vivo increased both IL-22 and IL-10 production in mice, which suggests that butyrate induction of IL-10 alone is insufficient to decrease colitis severity in this model.